SG&A Efficiency Analysis: Comparing Opthea Limited and Galapagos NV

Biotech SG&A: Opthea vs. Galapagos Expense Trends

__timestamp	Galapagos NV	Opthea Limited
Wednesday, January 1, 2014	9079000	2652041
Thursday, January 1, 2015	20309000	2361587
Friday, January 1, 2016	16945000	4472869
Sunday, January 1, 2017	20559000	5030957
Monday, January 1, 2018	29641000	4988941
Tuesday, January 1, 2019	88258000	5196412
Wednesday, January 1, 2020	162170000	6652774
Friday, January 1, 2021	167218000	18418247
Saturday, January 1, 2022	239528000	24827066
Sunday, January 1, 2023	94252000	41896408
Monday, January 1, 2024		15488619

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and Galapagos NV from 2014 to 2023. Galapagos NV, a Belgian biotech giant, has seen its SG&A expenses grow significantly, peaking in 2022 with a 2,500% increase from 2014. Opthea Limited, an Australian company, has also experienced a steady rise, with a notable 1,500% increase over the same period. Interestingly, 2023 marked a turning point for both companies, with Galapagos NV's expenses dropping by 60% from the previous year, while Opthea Limited's expenses surged by 68%. This divergence highlights the dynamic nature of the biotech industry, where strategic financial management can make or break a company's growth trajectory.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025